Does the media refer more to ENTA or SEPN?

In the previous week, Septerna had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for Septerna and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Septerna's score of 0.75 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ENTA or AVBP?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for ArriVent BioPharma and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat ArriVent BioPharma's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MPLT or ENTA?

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 1 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Maplight Therapeutics' score of 0.34 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENTA or XERS?

In the previous week, Xeris Biopharma had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Xeris Biopharma and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Xeris Biopharma's score of 0.54 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENTA or MRVI?

In the previous week, Maravai LifeSciences had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 5 mentions for Maravai LifeSciences and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Maravai LifeSciences' score of 0.95 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enanta Pharmaceuticals (ENTA) Competitors

$13.12 -0.62 (-4.48%)

As of 01:51 PM Eastern

Compare

ENTA vs. SEPN, AVBP, MPLT, XERS, and MRVI

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include Septerna (SEPN), ArriVent BioPharma (AVBP), Maplight Therapeutics (MPLT), Xeris Biopharma (XERS), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to Septerna?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Septerna had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for Septerna and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Septerna's score of 0.75 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has lower revenue, but higher earnings than Enanta Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.84	-$81.89M	-$2.59	N/A
Septerna	$45.95M	32.31	-$48.88M	-$0.81	N/A

Enanta Pharmaceuticals currently has a consensus price target of $20.29, indicating a potential upside of 54.56%. Septerna has a consensus price target of $45.89, indicating a potential upside of 39.33%. Given Enanta Pharmaceuticals' higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Enanta Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

Septerna has a net margin of -49.88% compared to Enanta Pharmaceuticals' net margin of -89.56%. Septerna's return on equity of -12.72% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Septerna beats Enanta Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Enanta Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Enanta Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.84	-$81.89M	-$2.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for ArriVent BioPharma and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat ArriVent BioPharma's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals presently has a consensus target price of $20.29, suggesting a potential upside of 54.56%. ArriVent BioPharma has a consensus target price of $44.83, suggesting a potential upside of 47.92%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. ArriVent BioPharma's return on equity of -48.98% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

Enanta Pharmaceuticals beats ArriVent BioPharma on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Maplight Therapeutics presently has a consensus price target of $39.10, suggesting a potential upside of 5.22%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 54.56%. Given Enanta Pharmaceuticals' higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Maplight Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Maplight Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Enanta Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Enanta Pharmaceuticals	$65.32M	5.84	-$81.89M	-$2.59	N/A

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 1 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Maplight Therapeutics' score of 0.34 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maplight Therapeutics and Enanta Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Enanta Pharmaceuticals currently has a consensus target price of $20.29, indicating a potential upside of 54.56%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 24.45%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Enanta Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.84	-$81.89M	-$2.59	N/A
Xeris Biopharma	$291.85M	5.13	$550K	$0.06	144.63

Xeris Biopharma has a net margin of 3.81% compared to Enanta Pharmaceuticals' net margin of -89.56%. Xeris Biopharma's return on equity of 735.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Xeris Biopharma	3.81%	735.00%	3.24%

In the previous week, Xeris Biopharma had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Xeris Biopharma and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Xeris Biopharma's score of 0.54 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Enanta Pharmaceuticals and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Maravai LifeSciences?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus price target of $20.29, suggesting a potential upside of 54.56%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential downside of 22.70%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Maravai LifeSciences has a net margin of -51.07% compared to Enanta Pharmaceuticals' net margin of -89.56%. Maravai LifeSciences' return on equity of -17.87% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Maravai LifeSciences had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 5 mentions for Maravai LifeSciences and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.02 beat Maravai LifeSciences' score of 0.95 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.84	-$81.89M	-$2.59	N/A
Maravai LifeSciences	$185.74M	9.89	-$130.77M	-$0.71	N/A

Summary

Enanta Pharmaceuticals beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$382.69M	$3.03B	$6.82B	$12.36B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-5.08	20.25	27.16	24.05
Price / Sales	5.84	778.53	573.09	112.68
Price / Cash	N/A	57.12	29.05	48.09
Price / Book	4.33	4.21	10.68	6.18
Net Income	-$81.89M	$65.46M	$3.59B	$331.63M
7 Day Performance	-3.78%	-2.56%	-1.56%	-1.49%
1 Month Performance	3.67%	-0.82%	1.10%	-1.21%
1 Year Performance	74.07%	17.30%	24.47%	17.67%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	2.3511 of 5 stars	$13.13 -4.5%	$20.29 +54.6%	+82.2%	$382.69M	$65.32M	N/A	160	News Coverage Positive News Analyst Forecast
SEPN Septerna	2.2545 of 5 stars	$35.83 +7.1%	$45.89 +28.1%	+166.1%	$1.62B	$45.95M	N/A	N/A	High Trading Volume
AVBP ArriVent BioPharma	2.0757 of 5 stars	$34.18 -0.9%	$43.14 +26.2%	+50.5%	$1.59B	N/A	N/A	40	Analyst Forecast
MPLT Maplight Therapeutics	1.4304 of 5 stars	$37.06 +5.8%	$38.80 +4.7%	N/A	$1.58B	N/A	N/A	109	Gap Down High Trading Volume
XERS Xeris Biopharma	3.1732 of 5 stars	$8.94 +6.8%	$10.80 +20.8%	+72.2%	$1.54B	$291.85M	149.00	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. SEPN, AVBP, MPLT, XERS, and MRVI

How does Enanta Pharmaceuticals compare to Septerna?

Summary

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does Enanta Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Enanta Pharmaceuticals compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. SEPN, AVBP, MPLT, XERS, and MRVI

How does Enanta Pharmaceuticals compare to Septerna?

Do insiders and institutionals believe in ENTA or SEPN?

Does the media refer more to ENTA or SEPN?

Which has stronger valuation & earnings, ENTA or SEPN?

Do analysts rate ENTA or SEPN?

Which has more volatility & risk, ENTA or SEPN?

Is ENTA or SEPN more profitable?

Summary

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Which has more volatility & risk, ENTA or AVBP?

Which has better valuation and earnings, ENTA or AVBP?

Does the media favor ENTA or AVBP?

Do analysts recommend ENTA or AVBP?

Do institutionals and insiders hold more shares of ENTA or AVBP?

Is ENTA or AVBP more profitable?

Summary

How does Enanta Pharmaceuticals compare to Maplight Therapeutics?

Do institutionals & insiders hold more shares of MPLT or ENTA?

Do analysts recommend MPLT or ENTA?

Is MPLT or ENTA more profitable?

Which has stronger valuation and earnings, MPLT or ENTA?

Does the media favor MPLT or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Do analysts rate ENTA or XERS?

Do insiders and institutionals have more ownership in ENTA or XERS?

Which has preferable valuation & earnings, ENTA or XERS?

Is ENTA or XERS more profitable?

Does the media prefer ENTA or XERS?

Which has more risk and volatility, ENTA or XERS?

Summary

How does Enanta Pharmaceuticals compare to Maravai LifeSciences?

Which has more risk & volatility, ENTA or MRVI?

Do analysts recommend ENTA or MRVI?

Is ENTA or MRVI more profitable?

Do insiders and institutionals hold more shares of ENTA or MRVI?

Does the media prefer ENTA or MRVI?

Which has better earnings & valuation, ENTA or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools